Novartis AG ADR (NVS)vsTheravance Biopharma Inc (TBPH)
NVS
Novartis AG ADR
$160.32
-0.04%
HEALTHCARE · Cap: $303.67B
TBPH
Theravance Biopharma Inc
$17.03
0.00%
HEALTHCARE · Cap: $884.18M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 54893% more annual revenue ($57.36B vs $104.31M). TBPH leads profitability with a 51.6% profit margin vs 17.5%. TBPH trades at a lower P/E of 16.4x. NVS earns a higher WallStSmart Score of 48/100 (D+).
NVS
Hold48
out of 100
Grade: D+
TBPH
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.8%
Fair Value
$95.76
Current Price
$160.32
$64.56 premium
Margin of Safety
+70.1%
Fair Value
$65.28
Current Price
$17.03
$48.25 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 34.3%
Every $100 of equity generates 27 in profit
Generating 4.8B in free cash flow
Keeps 52 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Attractively priced relative to earnings
Areas to Watch
Premium valuation, high expectations priced in
Trading at 8.1x book value
4.7% revenue growth
Grey zone — moderate risk
0.0% earnings growth
Smaller company, higher risk/reward
Revenue declined 20.9%
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Operating Margin, Return on Equity. Profitability is solid with margins at 17.5% and operating margin at 34.3%.
Bull Case : TBPH
The strongest argument for TBPH centers on Profit Margin, Debt/Equity, P/E Ratio. Profitability is solid with margins at 51.6% and operating margin at 8.9%.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.
Bear Case : TBPH
The primary concerns for TBPH are EPS Growth, Market Cap, Revenue Growth.
Key Dynamics to Monitor
NVS profiles as a value stock while TBPH is a declining play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.47 — expect wider price swings.
NVS is growing revenue faster at 4.7% — sustainability is the question.
NVS generates stronger free cash flow (4.8B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (48/100 vs 42/100), backed by strong 17.5% margins. TBPH offers better value entry with a 70.1% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Theravance Biopharma Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe, and Asia. The company is headquartered in George Town, the Cayman Islands.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?